We are live on ! Find out more
EDIT icon

Editas Medicine

215 hedge funds and large institutions have $1.15B invested in Editas Medicine in 2018 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 73 increasing their positions, 56 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 25

49% more call options, than puts

Call options by funds: $40.4M | Put options by funds: $27.1M

30% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 56

11% more capital invested

Capital invested by funds: $1.03B → $1.15B (+$119M)

9% more funds holding

Funds holding: 197215 (+18)

1.62% more ownership

Funds ownership: 66.44%68.05% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
215
Holders Change
+18
Holders Change %
+9.14%
% of All Funds
4.92%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
46
Increased
73
Reduced
56
Closed
25
Calls
$40.4M
Puts
$27.1M
Net Calls
+$13.2M
Net Calls Change
+$651K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$129M +$20.2M +571,862 +19%
BlackRock
2
BlackRock
New York
$124M +$20.9M +591,442 +21%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$104M -$40.7M -1,148,473 -28%
State Street
4
State Street
Massachusetts
$93M +$7.14M +201,541 +8%
Capital World Investors
5
Capital World Investors
California
$78.3M
AIM
6
ARK Investment Management
Florida
$78.2M +$19.9M +561,364 +35%
Morgan Stanley
7
Morgan Stanley
New York
$74.1M +$6.59M +186,018 +10%
DM
8
Deerfield Management
New York
$41.5M
Viking Global Investors
9
Viking Global Investors
Connecticut
$33.4M -$3.68M -103,903 -10%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$28.1M -$3.84M -108,454 -12%
CS
11
Credit Suisse
Switzerland
$19.9M -$3.41M -96,260 -15%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$19.7M +$59.7K +1,685 +0.3%
Northern Trust
13
Northern Trust
Illinois
$18.7M +$3.64M +102,901 +25%
GTP
14
Global Thematic Partners
New York
$18.2M +$1.17M +32,968 +7%
Deutsche Bank
15
Deutsche Bank
Germany
$16.3M -$1.52M -43,027 -9%
Chevy Chase Trust
16
Chevy Chase Trust
Maryland
$16.1M +$1.94M +54,850 +14%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$16M +$3.18M +89,734 +25%
Goldman Sachs
18
Goldman Sachs
New York
$12M -$252K -7,112 -2%
Federated Hermes
19
Federated Hermes
Pennsylvania
$11.1M +$1.96M +55,232 +22%
TA
20
Teachers Advisors
New York
$9.68M +$2.29M +64,555 +31%
Charles Schwab
21
Charles Schwab
California
$7.67M +$1.06M +29,981 +16%
UBS AM
22
UBS AM
Illinois
$7.13M +$1.34M +37,959 +24%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$6.92M -$378K -10,683 -5%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$6.67M +$2.24M +63,150 +51%
WCM
25
Wildcat Capital Management
New York
$6.65M

EDIT Hedge Fund Activity: Q2 2018 in Review

215 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2018, worth a combined $1.15B — up 11% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new EDIT positions and 25 closed out — a net gain of 21 holders — while 73 added to existing stakes and 56 trimmed.

The largest buyer was BlackRock, adding an estimated $20.9M. The largest seller was Fidelity Investments, cutting an estimated $40.7M.

  • 215 institutional investors held Editas Medicine (EDIT) as of Q2 2018, up from 197 in Q1 2018.
  • Funds reported $1.15B of Editas Medicine stock for Q2 2018, up 11% quarter-over-quarter.
  • 46 funds opened new Editas Medicine positions in Q2 2018 and 25 closed out, a net change of +21 holders.
  • The largest Editas Medicine buyer in Q2 2018 was BlackRock, an estimated $20.9M added.
  • The largest Editas Medicine seller in Q2 2018 was Fidelity Investments, an estimated $40.7M sold.

Based on aggregated 13F filings for Q2 2018.